Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a method of choice to treat many hematological malignancies as well as metabolic and autoimmune diseases. [1] [2] [3] However, graft-versus-host disease (GVHD) remains one of the most frequent and severe complications of alloHSCT. Even when HLA-identical siblings are the source of HSC for infusion, the likelihood of developing clinically significant acute and chronic GVHD approaches is 35 and 50%, respectively. 4, 5 Although steroids and other immunosuppressants are effective for acute GVHD, they increase the likelihood of infection regardless of whether the GVHD has been controlled or not. Furthermore, there is no effective therapy for severe steroid-refractory acute GVHD. Several drugs and antibodies have been used but with discouraging results. 6, 7 The removal of the donor T cells from the bone marrow graft has been shown to decrease the incidence of acute GVHD. To our disappointment, it is also associated with an increased incidence of relapse and graft failure. 8, 9 In addition to HSCs, bone marrow contains a second type of stem cellsFthe mesenchymal stem cells (MSCs) capable of giving rise to multiple mesenchymal lineages. 10, 11 They were shown to secrete a variety of colony-stimulating factors and cytokines, either constitutively or after stimulation. They could also support amplification of long-term culture-initiating cells in vitro and enhance engraftment in preclinical models. 12, 13 It has also been demonstrated that MSCs exhibit a potent immunosuppressive activity, which targets virtually all types of immune cells. [14] [15] [16] Given that the in vitro culture-expanded MSCs could be infused intravenous (i.v.) without toxicity, these preclinical studies were quickly translated into therapeutic applications that enhanced HSC engraftment and reduced the incidence and severity of GVHD. 17, 18 The aim of this pilot study was to investigate the potential benefits and side effects of cotransplanted MSCs related to their systemic immunosuppression in alloHSCT for the hematologic malignancy patients. In particular, the potential tumorigenesispromoting effect of MSCs was emphasized because several mouse transplantation studies revealed that MSCs favored tumor growth in vivo. 19, 20 Although our study did not support the role of MSCs to promote hematopoietic reconstitution at the dosage lower than those reported by others, we did demonstrate that MSCs transfusion could prevent GVHD. To our disappointment, we also found that cotransplantation of MSCs could result in disease relapse, which may be related to the systemic immunosuppression property of MSCs. (Table 1 ). All patients were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate visceral organ function (including a left ventricular ejection fraction of at least 50%, forced expiratory volume in 1 s and diffusion of carbon monoxide greater than 50% of predicted, serum direct bilirubin less than 2.0 mg per 100 ml and an actual or calculated creatinine clearance greater than 60 ml min À1 ). Patients were excluded if they had major central nervous system dysfunctions and active infection.
Materials and methods

Patients and study design
Harvesting and expansion of MSCs
After patient and donor enrollment, 40-60 ml of bone marrow aspirate was obtained under sterile conditions by puncturing posterior iliac crests of normal HLA-identical sibling donors. MSCs culture and expansion were undertaken by modifying methods previously published. 12 Briefly, the mononuclear cells were prepared by gradient centrifugation at 900 g for 30 min on Percoll (Sigma, St Louis, MI, USA) at a density of 1.073 g ml
À1
.
Then cells were resuspended in phosphate-buffered saline (PBS; Gibco, Grand Island, NY, USA) and centrifuged at 600 g for 10 min at 20 1C. Cells were resuspended at 1 Â 10 6 nucleated cells per milliliter in low-glucose Dulbecco's modified Eagle's medium (LG-DMEM; Invitrogen, Carlsbad, CA, USA), with selected 10% fetal bovine serum (FBS, StemCell Technologies, Vancouver, BC, Canada). A 15 ml portion of the suspension was plated per 75-cm 2 flask (Corning, NY, USA). MSCs were cultured at 37 1C in humidified incubators with 5% CO 2 and initially allowed to adhere for 72 h. Subsequent medium changes were performed every 3-4 days. When primary cultures were near confluence, the adherent cells were detached with 0.05% trypsin containing EDTA (Gibco, Grand Island, NY, USA), passaged and replated at a density of 1 
Conditioning and allogeneic HSC infusion
Blood samples of patients and donors were obtained for HLA-A, -B, -C, -DR and -DQ antigen typing, and HLA-DRB1 alleles were assessed by using sequence-specific oligonucleotide probes. 21 At the start of the study, we selected either bone marrow or peripheral blood stem cells (PBSC) as the source of cellular rescue. Donor allogeneic HSCs were obtained by using either a standard bone marrow harvest technique or a PBSC apheresis procedure with standard pheresis equipment after 
MSCs infusion
The planned MSCs dose-escalation scheme was 1.0-2.0 Â 10 6 kg À1 in both the patients receiving bone marrow and those receiving PBSC. Because of the time constraints required by patient transplantation protocols, there were some difficulties in growing sufficient MSCs on time for patient infusion as to the group assigned to receive the 1.0-2.0 Â 10 6 kg À1 dose; only two patient/donor pairs were able to achieve this dose. As a result, the range of MSCs dose in the study became 0.3-15. 
Prophylaxis and treatment of GVHD
A standard therapy of methotrexate plus cyclosporine was used for GVHD prophylaxis. 25 It consisted of intravenous cyclosporine 3 mg kg À1 d À1 in divided doses beginning on the day before transplantation (day À1) and continued. Methotrexate was administered i.v. at a dose of 15 mg m À2 on day 1, and 10 mg m À2 on days 3 and 6 after HSC transplantation. Patients were advanced to oral cyclosporine once they could tolerate. In the absence of GVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued for 6 months after transplantation or relapse. Acute and chronic GVHD were treated according to institutional practices.
Engraftment, GVHD grading and tumor assessment
Time to neutrophil engraftment was defined as the first of the 3 consecutive days in which the absolute neutrophil count exceeded 0.5 Â 10 9 l
À1
. Time to platelet engraftment was defined as, the first of the 3 consecutive days in which the platelet count exceeded 50 Â 10 9 l
. Acute GVHD (onset within 100 days of transplantation) was graded 0-IV (grades II-IV were considered moderate to severe) according to the published criteria. 26 Chronic GVHD was graded as limited or extensive according to the published criteria in patients who survived more than 90 days with evidence of engraftment. 27 Patients underwent restaging with external imaging techniques and diagnostic marrow examinations as appropriate for each malignancy every 1-3 months after HSC infusion. Relapse is defined as the recurrence of disease. Death in the absence of persistent relapse is categorized as non-relapse mortality.
Supportive care
All patients had multilumen indwelling central venous catheters and were kept in single rooms for taking care. Antibiotics were administered empirically for fever and neutropenia according to institutional guidelines, and all patients were supported with irradiated blood components in an attempt to maintain the hematocrit greater than 25% and the platelet count greater than 10 Â 10 9 l À1 or to treat bleeding complications due to thrombocytopenia. Recombinant hematopoietic growth factors were administered routinely. Supportive care also included the use of ganciclovir with or without intravenous immunoglobulin for cytomegalovirus (CMV) reactivation and Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulfamethoxazole. Antifungal agent prophylaxis with fluconazole, amphotericin B or itraconazole was administered empirically.
Statistical analysis
Estimates of disease-free and overall survival and relapse were obtained by using Kaplan-Meier methods according to the SPSS version 13.0. Follow-up was censored at the date of last contact among survivors. Cumulative incidence rates of grades I-IV acute GVHD, chronic GVHD and relapse/progression were computed to allow for competing risks. The statistical significance for engraftment was assessed by Student's t-test or the Wilcoxon signed rank-sum test. Tests resulting in a P-value under 0.05 were considered to be significant.
Results
Patient disposition and characteristics
Baseline patient characteristics are summarized in Table 1 . Median patient age and clinical stage were similar in the two groups. The median patient age was 38 years (range, 17-52 years) in MSCs group and 37 years (range, 16-61 years) in nonMSCs group, respectively. Most patients were males (n ¼ 11 in MSCs group and n ¼ 13 in non-MSCs group). Acute myeloid leukemia was the most common diagnosis (n ¼ 8 and n ¼ 7, respectively). We failed to expand adequate numbers of MSCs from bone marrow of 5 donors. Thus a total of 10 patients were allocated to MSCs group with written informed consent. Expansion of MSCs up to 1.0-2.0 Â 10 6 cells/kg of recipient weight from donor bone marrow was achieved in 2 (13.3%) of the 15 donors, and expansion of MSCs up to 0.3 Â 10 5 -9.0 Â 10 5 kg À1 was achieved in 8 (53.3%) of the 15 donors. Among the 10 patients with MSCs infusion, 4 received bone marrow transplantation, 4 received peripheral blood stem cell transplantation and 2 received bone marrow plus PBSC transplantation. A total of 15 patients in the control group successfully underwent HSCT (5 received bone marrow transplantation, 9 received peripheral blood stem cell transplantation and 1 received bone marrow plus PBSC transplantation). All patients completed the study through the 3-year follow-up evaluation. The median bone marrow volume aspirated for MSCs culture was 50 ml (range, 40-60 ml). The median culture time of MSCs was 32 days (range, 21-56 days).
Safety
Mesenchymal stem cells were infused in 30 min through a central venous line in 10 patients. There was no acute toxicity after transplant.
Engraftment
Overall, only one patient from the MSCs group failed to reach a sustained absolute neutrophil count of more than 0.5 Â 10 9 l
À1
and a sustained platelet count of more than 50 Â 10 9 l À1 before death at day 19 after transplantation. The hematopoietic cell Cotransplantation of MSC in hematologic malignancy patients H Ning et al doses and neutrophil and platelet engraftment are summarized in Table 1 . Compared with the non-MSCs individuals the MSCs group took one more day to reach absolute neutrophil count 40.5 Â 10 9 l À1 on average and the difference was statistically insignificant (P ¼ 0.9108). Similarly, patients in MSCs group achieved a platelet count 450 Â 10 9 l À1 3 days later than those in non-MSCs group (P ¼ 0.5366).
Graft-versus-host disease
The details of incidence and severity of GVHD are summarized in Tables 2 and 3 . One patient in the MSCs group was not graded for acute GVHD because of early death after 19 days of transplantation. Only 1 patient (11.1%) in MSCs group developed grade II acute GVHD as compared with 8 (53.3%) of 15 in the non-MSCs group. None in either group developed grades III-IV acute GVHD. The overall incidence of acute GVHD was 44.4% (4/9) in the MSCs group, compared with 73.3% (11/15) in the non-MSCs group. One (14.3%) of the 7 evaluable patients in the MSCs group survived at least 90 days after transplantation experienced limited chronic GVHD. Four (28.6%) of the 14 evaluable patients in the non-MSCs group experienced chronic GVHD, 1 limited and 3 extensive. Relapse Six (60.0%) of the 10 patients in the MSCs group experienced tumor relapse at the median time of 63 days (range, 39-1062 days), compared with 3 (20.0%) of the 15 patients in the nonMSCs group at the median time of 177 days (range, 66-450 days). Relapse rate of MSCs group is significantly higher than that of non-MSCs group (log rank: P ¼ 0.020; Breslow: P ¼ 0.019). The details are shown in Table 2 and Figure 1 . In the MSCs group, most relapse occurred within 6 months after transplantation.
Early and mid-phase infection
Survival
With a median follow-up of 36.6 months (0.6-44.0 months), six patients in the MSCs group (n ¼ 10) and five patients in the 
Relapse and GVHD are not correlated with MSCs dose
Correlations between the MSCs dose and relapse or GVHD was evaluated by logistic regression analysis and shown as scatterplots. As shown in Figure 3 , the results did not show any significant correlation between the MSCs dose and relapse (P ¼ 0.8995). Moreover, there was no significant correlation between the MSCs dose and GVHD (P ¼ 0.2639).
Discussion
The key finding of the study is the strikingly increased frequency of disease relapse in malignant hematological patients infused with MSCs. Relapse occurred in 60.0% of the patients in the MSCs group compared with 20.0% in the non-MSCs group. Furthermore, the median time from transplantation to relapse was much earlier in MSCs group (63 days) than non-MSCs group (177 days). It is noteworthy that 80% (8 in 10) of patients in the MSCs group and 73% (11 in 15) of patients in the non-MSCs group were in CR1, CP or RAS stages before transplantation. The 3-year disease-free survival was 30.0 and 66.7% in the MSCs and non-MSCs group, respectively. Collectively, the results corroborated the previous findings that MSCs may favor tumor growth in vivo. In fact, MSCs were capable of inhibiting allogeneic T-cell response and suppress T-cell proliferation by cell/cell interactions and soluble factors. 15, 16, 28, 29 Conversely, suppressed T-cell function had the potential to abrogate or weaken graft-versus-leukemia activity in the allograft setting. There are no indications that MSCs could selectively suppress GVHD but not graft-versus-leukemia. 30 In melanoma, simultaneous administration of MSCs and allogeneic tumor cells resulted in accelerated tumor growth even when MSCs were delivered to a distant site, suggesting that MSCs may suppress systemic immune function. 19 Another report indicated a discrepancy between the in vitro and in vivo behavior of MSCs. They inhibit the proliferation of malignant cells of hematopoietic and non-hematopoietic origin in vitro by transiently arresting the tumor cells in the G1 phase of cell cycle. However, when tumor cells were injected into NOD/SCID mice in conjunction with MSCs, the tumor growth was much faster as compared with the group receiving only tumor cells. The authors propose that MSCs may preserve the self-renewal ability of cancer cells and is a new mechanism by which stromal environment can influence the course of malignant diseases. 31 Actually, the planned enrollment of patients was 25 patients in each group at the beginning, but the unexpected side effect led us to foreclose this clinical trial. Given that the patient sample size is small in this study, further evaluation of potential beneficial and/or undesirable effects of MSCs transplantation on the balance between graft-versus-host and graft-versus-leukemia reactions is needed for hematologic malignancy diseases.
Another finding is that cotransplantation of MSCs could prevent GVHD even at the dosage less than what was previously administered for hematopoietic recovery, in accordance with several previous reports. 17, 18, 32, 33 In this trial, all patients received the GVHD prophylaxis regimen of cyclosporine and methotrexate therapy on days 1, 3 and 6. Acute GVHD did not develop in 55.6% (5/9) patients in the MSCs group compared with 26.7% (4/15) in the non-MSC group. Grades II-IV acute GVHD occurred only in 11.1% evaluable patients in the MSCs group compared with 53.3% in the non-MSCs group. None in either group developed grades III-IV GVHD. The overall incidence of acute GVHD was 44.4 (4/9) and 73.3% (11/15) in the MSCs and non-MSCs group, respectively. The results were comparable with previous reports in sibling-matched allogeneic stem cell transplantation patients, 44-64 and 12-26% for grades II-IV GVHD and grades III-IV GVHD, respectively. [34] [35] [36] [37] [38] Nevertheless, extensive chronic GVHD rates in these reports (ranged from 30 to 46%) are absent in the MSCs group, whereas 21.4% in the non-MSCs group. Recently, Tisato et al. 39 reported that MSCs from umbilical cord blood are effective in preventing GVHD. Therefore, it is interesting to investigate the correlation of umbilical cord blood-MSCs transplantation and side effects in the future. ). In contrast with the past report, MSCs were capable of producing cytokines to support hematopoiesis, and, therefore, potentially enhanced marrow recovery. 40, 41 We found no evidence that MSCs can enhance hematopoietic recovery. The median time to neutrophil recovery 40.5 Â 10 9 l À1 for MSCs group and non-MSCs group were 16 and 15 days, respectively. In addition, the median time to platelet engraftment was comparable (30 vs 27 days). An explanation for this result is that the cotransplanted number of MSCs was much lower than that in the past report. 40 A recent study demonstrates that cotransplantation with human MSCs can enhance the engraftment of human hematopoietic stem cells in a dose-dependent fashion in NOD/SCID mice. 42 In some cases, hematopoietic reconstitution after autologous bone marrow transplantation was enhanced by infusing patientderived MSCs at the dosage of 1.0-2.8 Â 10 6 cells/kg, which was similar to those reported by Loc ON et al. 12 (X Lou, HM Ning, H Chen, unpublished data). However, using the same method, in 13 donor/recipient pairs, we were unable to expand a homogeneous population of donor MSCs that were sufficient enough to provide a dose of 1.0-2.0 Â 10 6 cells/kg in a timely fashion (within 32 days) from a small bone marrow aliquot. Considering the worry of tumor progression while attempting to harvest the target dose of MSCs as well as adequate numbers of HSC, only 10 patients received culture-expanded MSCs infusions in a number of 0.3 Â 10 5 -15.3 Â 10 5 kg À1 at last. Although this is a small pilot study with patients of different diagnoses and disease stages, it indicates that MSCs may be a double-edged sword, which can prevent or treat GVHD due to their immunomodulatory properties, but at the same time they may have the potential to abrogate or weaken graft-versus-leukemia activity. On the basis of our data, we suggest that MSCcotransplantation in alloHSCT should be applied in the non-malignant hematopoietic diseases other than malignant hematopoietic diseases at present. Further large-scale randomized studies are needed to evaluate the potential benefits and hazards of MSC-cotransplantation in malignant hematopoietic diseases.
